ProCE Banner Activity

Role of Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Slideset Download
Downloadable slides on leveraging immune checkpoint inhibitors for perioperative treatment of patients with early-stage triple-negative breast cancer.

Released: June 03, 2022

Expiration: June 02, 2023

No longer available for credit.

Share

Faculty

Rita Nanda

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Rita Nanda, MD, has disclosed that she has received funds for research support from Arvinas, AstraZeneca, Celegent, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, and Taiho and has served on advisory boards for AstraZeneca, BeyondSpring, Cardinal Health, Fuji Film, Immunomedics/Gilead Infinity, iTeos, MacroGenics, Merck, OBI, OncoSec, and Seattle Genetics.